The maker of a drug for Lou Gehrig’s disease, Amylyx Pharmaceuticals, has announced the voluntary withdrawal of the medicine from the market following its failure in a large study. The drug, Relyvrio, did not demonstrate efficacy in helping patients with the deadly neurological condition, prompting the company to cease sales and marketing in the U.S. and Canada.
Despite receiving FDA approval in September 2022, Relyvrio's lack of effectiveness has led to its removal from the market, leaving only three ALS medicines available to U.S. patients. This decision has been met with disappointment by patients and advocates who have been advocating for more treatment options for ALS.
